Impilo Orphan Drugs AB is a private equity fund based in Stockholm, Sweden. According to its most recent Form D, filed Sep 30, 2024, it has sold $80,458,243 of interests to 12 investors since its first sale in Sep 2024. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Johan Odin; Karl Gustav Johan Jungdalen Lundgren; Tor Ulf Hubendick.
- Total raised
- $80,458,243Cumulative sales reported on Form D
- Investors
- 12
- First sale
- Sep 19, 2024
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Johan Odin; Karl Gustav Johan Jungdalen Lundgren; Tor Ulf Hubendick
- Latest Form D
- Sep 30, 2024
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about Impilo Orphan Drugs AB
What is the minimum investment for Impilo Orphan Drugs AB?
Impilo Orphan Drugs AB's latest Form D, filed Sep 30, 2024, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in Impilo Orphan Drugs AB?
Impilo Orphan Drugs AB is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has Impilo Orphan Drugs AB raised?
Impilo Orphan Drugs AB reports $80,458,243 sold from 12 investors on its Form D filed Sep 30, 2024. This is cumulative sales since the offering began, not current assets or performance.
Where is Impilo Orphan Drugs AB based?
Impilo Orphan Drugs AB is based in Stockholm, Sweden.
When did Impilo Orphan Drugs AB launch?
Impilo Orphan Drugs AB reports its first sale in Sep 2024.
Size compared with every private equity fund
Raised more than 90% of the 30 private equity funds based in Sweden, and more than 70% of all 8,950 that report sales.